Sensing No Room For Price Compromise, Janssen Pulls Invokana From Germany
This article was originally published in The Pink Sheet Daily
After a disappointing assessment from Germany’s two reimbursement bodies, Janssen has opted to withdraw it diabetes drug, believing it cannot secure a competitive price.
You may also be interested in...
Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.
Germany’s new grand coalition government includes a health minister with no background in health care.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.